B O O K - American College of Rheumatology

ACR/ARHP Poster Session C
Immunology and Rheumatology, Academic Medical Center
/ University of Amsterdam, Amsterdam, The Netherlands,
4
Division of Clinical Immunology and Rheumatology, Academic
Medical Center, University of Amsterdam, Amsterdam, The
Netherlands, 5 Division of Nuclear Medicine, Academic Medical
Center, University of Amsterdam, Amsterdam, The Netherlands,
6
Landsteiner Laboratory, Department of Experimental
Immunohematology, Sanquin Research, Amsterdam, The
Netherlands, 7 Millennium Pharmaceuticals, Inc, Department of
Research and Development, Cambridge, MA.
1823. Multiple Regression Analysis on the Clinical Parameters
Associating with Clinical, Structural and Functional Remission
at 52 Weeks in RA Patients Treated with Anti-IL-6 Receptor
Antibody, Tocilizumab – REACTION-2 Study. Tsutomu Takeuchi 2 ,
Yoshiya Tanaka 5 , Kouichi Amano 1 , Eri Sato 4 , Masao Nawata 5 ,
Hayato Nagasawa 1 , Daisuke Hoshi 4 , Kazuyoshi Saito 5 , Syunsuke
Fukuyo 5 , Kentarou Hanami 5 , Takahiko Kurasawa 1 , Hideto
Kameda 3 and Hisashi Yamanaka 4 , 1 Division of Rheumatology and
Clinical Immunology, Department of Internal Medicine, Saitama
Medical Center, Saitama Medical University, Saitama, Japan,
2
Division of Rheumatology, School of Medicine, Keio University,
Tokyo, Japan, 3 Division of Rheumatology, School of Medicine,
Keio University, Tokyo, Japan, 4 Institute of Rheumatology,
Tokyo Women’s Medical University, Tokyo, Japan, 5 The
First Department of Internal Medicine, School of Medicine,
University of Occupational &Environmental Health, Kitakyushu,
Japan.
1824. Outcome of Interstitial Lung Disease (ILD) after Administration
of Biologics in Patients with Pre-Existing ILD in RA. Shinji
Motojima 1 , Tamao Nakashita 1 , Akira Inoue 1 , Kei-ichi Inoue 1
and Natsuki Fujio 2 , 1 Department of Rheumatology and Allergy,
Kameda Medical Center, Kamogawa, Chiba, Japan, 2 Department
of Rheumatology and Allergy, Kameda Medical Center, Japan.
1825. Patients Not Responding to Etanercept Obtain Lower Trough
Etanercept Concentrations Compared to Responding Patients.
Anna Jamnitski 1 , Michael T. Nurmohamed 1 , Margreet M. Hart 2 ,
Ben A. Dijkmans 3 , Lucien Aarden 2 and Gerrit Jan Wolbink 1 , 1 Jan
van Breemen Institute, 2 Sanquin Research, 3 VU Medical Center.
1826. Prevalence and Persistence of Low Infliximab Serum Trough
Levels in RA Patients with Low Disease Activity in Daily Clinical
Practice. Aatke van der Maas 3 , Alfons A. Den Broeder 4 , Gert-Jan
Wolbink 1 , Frank H. J. van den Hoogen 4 , Piet L. C. M. van Riel 5
and Bart J. F. van den Bemt 2 , 1 Department of Immunopathology,
Sanquin Research, Amsterdam, The Netherlands, 2 Department
of Pharmacy, St. Maartenskliniek, Nijmegen, The Netherlands,
3
Department of Rheumatology, St. Maartenskliniek, Nijmegen,
The Netherlands, 4 Department of Rheumatology, St.
Maartenskliniek, Nijmegen, The Netherlands, 5 Department of
Rheumatology, St. Radboud UMCN, Nijmegen, The Netherlands.
1827. Regulatory T Cells from Patients with Rheumatoid Arthritis
Are Not Affected by Adalimumab and Etanercept. Thierry
Lequerré 3 , Céline Blache 2 , Stéphanie Beuteux 2 , Arnaud
Roucheux 1 , Ingrid Dedreux 1 , Serge Jacquot 1 , Xavier Le
Loët 4 , Olivier Boyer 1 and Olivier Vittecoq 4 , 1 Department of
Immunology, Inserm905, Rouen University Hospital, University
of Rouen, 2 Inserm905, University of Rouen, 3 Rheumatology
Department, Inserm905, Rouen University Hospital, University
of Rouen, Rouen, France, 4 Rheumatology Department,
Inserm905, Rouen University Hospital, University of Rouen.
1828. Relationship between Rituximab Serum Levels and Progression
of Structural Damage in Rheumatoid Arthritis Patients. Maria
J. H. Boumans 2 , Y. K. O. Teng 6 , Rogier M. Thurlings 3 , Koen Vos 4 ,
Steven O. Stapel 7 , Gertjan Wolbink 5 , Janneke Tekstra 8 and Paul
P. Tak 1 , 1 Academic Med Ctr/Univ of Amsterdam, Amsterdam,
The Netherlands, 2 Academic Medical Center/University of
Amsterdam, Amsterdam, Noord-Holland, The Netherlands,
3
Academic Medical Center/University of Amsterdam, 4 Academic
Medical Center/University of Amsterdam/Jan van Breemen
Institute, 5 Jan van Breemen Institute, Sanquin Research,
Amsterdam, 6 Leiden University Medical Center, 7 Sanquin
Research, Amsterdam, 8 University Medical Centre, Utrecht.
1829. Response, Remission, and Flare during Early Treatment
of Rheumatoid Arthritis with Infliximab. Ronald F. Van
Vollenhoven 2 , Dimitrios Boumpas 10 , Rene Westhovens 9 ,
Marek Brzosko 7 , Karin E. Svensson 8 , Olav Bjorneboe 3 , Cees
Meeuwisse 5 , Shankar Srinivasan 4 , Nathan Vastesaeger 6 and
Philippe Gaudin 1 , 1 CHU Hôpital Sud, Echirolles Cedex, France,
2
Karolinska University Hospital, Stockholm, Sweden, 3 Martina
Hansens Hospital, Gjettum, Norway, 4 Merck and Company, Inc,
Kenilworth, NJ, 5 MSD, Oss, The Netherlands, 6 MSD, Brussels,
Belgium, 7 Pomeranian Medical University, Szczecin, Poland,
8
Skövde Hospital, Skövde, Sweden, 9 University Hosp KU Leuven,
Leuven, Belgium, 10 University Hospital of Heraklion, Heraklion
Crete, Greece.
1830. Rituximab (RTX) Is More Effective in Active Sero-Positive RA
Than Sero-Negative RA. Abdul Khan 3 , Taher Mahmud 4 , Tony
Hammond 1 , Mike Batley 2 and Alison Leak 5 , 1 Maidstone General
Hospital Hermitage Lane Maidstone Kent, Maidstone, Kent,
United Kingdom, 2 Maidstone General Hospital Maidstone Kent,
Maidstone, Kent, United Kingdom, 3 Maidstone General Hospital,
Maidstone, Kent, Maidstone, Kent, United Kingdom, 4 Pembury
Hospital, Pembury, Kent, United Kingdom, 5 Queen Elizabeth
Queen Mother Hospital, Margate, Kent, United Kingdom.
1831. Safety and Efficacy of IL-1 Trap in Resistant Adult Onset Still’s
Disease: 24 Month Follow-Up of Open Label Treatment and
Biomarkers of Response. Cailin Henderson, Mildred Wilson,
Tuyet-Hang Pham, Gregory Dolan, Adriana Gobbo, Christopher
Snyder, Elizabeth Joyal and Raphaela Goldbach-Mansky, NIAMS
/ NIH.
1832. Safety, Efficacy, and Sustained Improvements in Household
Productivity and Daily Activities with Certolizumab Pegol (CZP)
Monotherapy over 2 Years in Patients with Active Rheumatoid
Arthritis (RA). Roy M. Fleischmann 4 , Ernest Choy 3 , Ronald van
Vollenhoven 2 , Niti Goel 6 , Oana Purcaru 5 , Kristel Luijtens 5 and
Vibeke Strand 1 , 1 Division of Immunology and Rheumatology,
Stanford University School of Medicine, Palo Alto, CA,
2
Karolinska Institute, Stockholm, Sweden, 3 Kings College
Hospital, London, United Kingdom, 4 MCRC, University of Texas,
Dallas, TX, 5 UCB, Brussels, Belgium, 6 UCB, Smyrna, GA.
1833. Statins Inhibit the Anti-Rheumatic Effects of Rituximab in
Rheumatoid Arthritis – Results from the Dutch Rheumatoid
Arthritis Monitoring (DREAM) Registry. Elke Arts 4 , Tim L.
Jansen 2 , Alfons Den Broeder 6 , Harald E. Vonkeman 3 , Ellen
Dutmer 1 , Mart A. F. J. Van de Laar 3 , Piet L. C. M. Van Riel 5 and
Jaap Fransen 5 , 1 Gelderse Vallei Hospital Ede, 2 Medical Centre
Leeuwarden, 3 Medisch Spectrum Twente &University of Twente,
4
Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands, 5 Radboud University Nijmegen Medical Centre,
6
Sint Maartenskliniek.
2010 Program Book 261